About
Therapies for Immunological and Inflammatory Disorders
Areas of Focus
Categories
Boston & New England
Team (16)
Clinical Trials (4)
View allTotal Trials
4
As Lead Sponsor
4
As Collaborator
0
Total Enrollment
862
By Phase
PHASE1: 2PHASE2: 2
By Status
RECRUITING: 3ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT07027527Lead Sponsor
An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis
PHASE1Recruiting
50 participants
Started: Jun 4, 2025 · Completed: Oct 31, 2027
NCT07003425Lead Sponsor
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
PHASE2Recruiting
350 participants
Started: May 14, 2025 · Completed: Dec 31, 2029
NCT06920901Lead Sponsor
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma
PHASE1Active, not recruiting
31 participants
Started: Mar 27, 2025 · Completed: Mar 31, 2027
NCT06395948Lead Sponsor
A Study Evaluating APG777 in Atopic Dermatitis
PHASE2Recruiting
431 participants
Started: Apr 29, 2024 · Completed: Jun 30, 2028
Locations (1)
Headquarters
Waltham, MA, United States
Map
Loading map...